Entheon Biomedical Corp. announced that the company has terminated Andrew Hegle's position as Chief Science Officer, effective July 31, 2023. Mr. Hegle will continue on the Company's Board of Directors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.165 CAD | -23.26% | -23.26% | +65.00% |
04-29 | Entheon Biomedical Corp. Reports Earnings Results for the First Quarter Ended February 29, 2024 | CI |
04-18 | Entheon Biomedical Corp. announced that it has received CAD 0.1475 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
+65.00% | 1.07M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- ENBI Stock
- News Entheon Biomedical Corp.
- Entheon Biomedical Corp. Announces Termination of Andrew Hegle as Chief Science Officer